United Therapeutics (NASDAQ:UTHR – Get Rating) had its target price hoisted by Argus from $250.00 to $300.00 in a research note published on Wednesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company's stock.
A number of other analysts also recently weighed in on the stock. UBS Group started coverage on shares of United Therapeutics in a research report on Tuesday, December 6th. They set a buy rating and a $320.00 price target on the stock. The Goldman Sachs Group initiated coverage on United Therapeutics in a research note on Monday, December 5th. They issued a sell rating and a $230.00 price target on the stock. Morgan Stanley upped their price objective on United Therapeutics from $322.00 to $330.00 and gave the stock an overweight rating in a research report on Tuesday, December 6th. Wedbush lifted their target price on United Therapeutics from $250.00 to $305.00 in a research report on Thursday, November 3rd. Finally, JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $240.00 to $265.00 and gave the stock an overweight rating in a report on Thursday, November 3rd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $283.64.
Get United Therapeutics alerts:United Therapeutics Trading Down 0.2 %
Shares of UTHR stock opened at $261.04 on Wednesday. The stock has a market cap of $11.90 billion, a P/E ratio of 17.76, a price-to-earnings-growth ratio of 1.56 and a beta of 0.62. United Therapeutics has a 1 year low of $158.38 and a 1 year high of $283.09. The company has a current ratio of 9.68, a quick ratio of 9.39 and a debt-to-equity ratio of 0.18. The stock has a 50 day simple moving average of $271.03 and a 200 day simple moving average of $240.39.
United Therapeutics (NASDAQ:UTHR – Get Rating) last released its earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.57 by $1.34. The company had revenue of $516.00 million for the quarter, compared to analyst estimates of $492.92 million. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. On average, research analysts predict that United Therapeutics will post 16.63 earnings per share for the current fiscal year.Insider Buying and Selling
In related news, Director Nilda Mesa sold 290 shares of the business's stock in a transaction on Monday, November 7th. The shares were sold at an average price of $268.57, for a total value of $77,885.30. Following the sale, the director now owns 6,180 shares of the company's stock, valued at $1,659,762.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Nilda Mesa sold 290 shares of the business's stock in a transaction on Monday, November 7th. The shares were sold at an average price of $268.57, for a total value of $77,885.30. Following the sale, the director now owns 6,180 shares of the company's stock, valued at $1,659,762.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Louis W. Sullivan sold 700 shares of the business's stock in a transaction on Tuesday, November 1st. The stock was sold at an average price of $230.28, for a total transaction of $161,196.00. Following the completion of the sale, the director now directly owns 12,180 shares in the company, valued at approximately $2,804,810.40. The disclosure for this sale can be found here. Insiders have sold a total of 183,390 shares of company stock valued at $48,335,135 over the last 90 days. 12.40% of the stock is owned by insiders.
Institutional Trading of United Therapeutics
Institutional investors have recently bought and sold shares of the company. Calamos Advisors LLC bought a new stake in United Therapeutics during the second quarter valued at $525,000. UMB Bank n.a. boosted its position in United Therapeutics by 91.8% during the second quarter. UMB Bank n.a. now owns 1,306 shares of the biotechnology company's stock valued at $308,000 after acquiring an additional 625 shares during the last quarter. Hallmark Capital Management Inc. bought a new stake in United Therapeutics during the second quarter valued at $33,000. Roman Butler Fullerton & Co. bought a new stake in United Therapeutics during the second quarter valued at $1,573,000. Finally, TriaGen Wealth Management LLC bought a new stake in United Therapeutics during the second quarter valued at $320,000. Institutional investors own 95.63% of the company's stock.
About United Therapeutics
(Get Rating)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.